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Effect estimates from randomized trials and observational studies may not be directly comparable 
because of differences in study design, other than randomization, and in data analysis. We propose a 
three-step procedure to facilitate meaningful comparisons of effect estimates from randomized trials 
and observational studies: 1) harmonization of the study protocol (eligibility criteria, treatment 
strategies, outcome, start and end of follow-up, causal contrast) so that the studies target the same 
causal effect, 2) harmonization of the data analysis to estimate the causal effect, and 3) sensitivity 
analyses to investigate the impact of discrepancies that could not be accounted for in the harmonization 
process. To illustrate our approach, we compared estimates of the effect of immediate with deferred 
initiation of antiretroviral therapy in individuals positive to the human immunodeficiency virus from the 
START randomized trial and the observational HIV-CAUSAL Collaboration.  
 
 








Randomized trials and observational studies are used to estimate the comparative effectiveness and 
safety of clinical strategies. When a randomized trial and an observational study address a similar 
question, discrepancies between their effect estimates tend to be attributed to uncontrolled 
confounding (due to imbalance of prognostic factors between the treatment groups) in the 
observational study. However, such discrepancies can also be explained by differences in study design 
and data analysis.  
 
For example, the randomized-observational discrepancy for the effect of postmenopausal estrogen plus 
progestin therapy on coronary heart disease was largely explained by selection bias (because the follow-
up in the observational study started some time after initiation of therapy) whereas unmeasured 
confounding seemed to play a lesser role (1, 2). As another example, randomized trials tend to use 
intention-to-treat estimates that quantify the effect of being assigned to treatment, regardless of 
whether treatment is actually received, whereas many observational studies quantify the effect of the 
treatment that was actually received (3).  
 
If differences other than randomization are not explicitly taken into account, randomized-observational 
comparisons, as commonly undertaken in meta-analyses (4-8), may be hard to interpret because they 
generally compare “apples with oranges” rather than “apples with apples”. Informative comparisons 
between randomized and observational estimates will often require a careful re-analysis of the data of 




Here, we describe a systematic approach to improve the comparison of effect estimates from a 
randomized trial and an observational study. Our approach has three stages: 1) harmonization of the 
study protocol to ensure that the studies target the same causal effect, 2) harmonization of the data 
analysis to target a common estimand, and 3) sensitivity analyses to investigate the impact of any 
remaining discrepancies.  
 
We illustrate our systematic approach through a case study: a comparison of the INSIGHT Strategic 
Timing of Antiretroviral Therapy (START) randomized trial (9) and an observational analysis of routinely 
collected data in the HIV-CAUSAL Collaboration (10). Both studies compared the effectiveness of 
strategies for initiation of antiretroviral treatment in human immunodeficiency virus (HIV)-positive 
individuals. Both studies found that immediate initiation of antiretroviral therapy was beneficial, but the 
magnitude of the estimated benefit appeared to differ. 
 
 
Case study: Initiation of antiretroviral therapy in HIV-positive individuals 
Antiretroviral therapy (ART) is a life-long treatment for HIV-positive individuals (11, 12). Historically, the 
decision of initiating ART was guided by the CD4 cell count (low levels indicate severe 
immunosuppression). During the 2000s, a key question was at which CD4 count should ART be initiated. 
Results from randomized trials (9, 13-15) and observational studies (6, 9, 10, 13-21) led to the now 
widely accepted conclusion that ART should be initiated as soon as possible after diagnosis of HIV 
infection. The two most recent studies, the randomized START trial (9) and the observational HIV-
CAUSAL Collaboration(10), compared the effectiveness of immediate initiation regardless of CD4 count 
versus deferred initiation until CD4 count dropped below 350 cells/mm3 or acquired immunodeficiency 
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syndrome (AIDS) was diagnosed in HIV-positive, AIDS-free, and treatment-naïve individuals with CD4 
count>500 cells/mm3 at the start of the study.  
 
The START trial included 4685 individuals from low, middle and high-income countries. The intention-to-
treat hazard ratio for immediate vs. delayed initiation for the primary outcome (the earliest of any 
serious AIDS-related event, serious non-AIDS-related event, or death) was 0.43 (95% confidence interval 
[CI] 0.30,0.62) and the per-protocol hazard ratio was 0.34 (0.21,0.52) (22). 
 
The HIV-CAUSAL study included 17,612 individuals from cohorts in 9 countries in Europe and the 
Americas (23-25). All cohorts record routinely collected clinical data on patient characteristics, ART use, 
CD4 count, HIV-RNA, AIDS-defining illnesses, and deaths. The 7-year risk ratio of AIDS or death for 
immediate vs. deferred initiation was 0.66 (95% CI 0.56, 0.75) and the risk difference 2.5% (95% CI 1.8, 
3.2).  
 
At a first glance, the estimated effect of immediate initiation appeared more beneficial in the 
randomized trial than the observational study. However, the effect estimates were not directly 
comparable as the two studies presented several key differences summarized in the outer columns of 
Web Figure 1. In the next sections, we describe a process to harmonize their study design and data 
analysis. 
 
Stage 1: Harmonization of study protocol 
The first stage of our systematic approach requires an explicit description of the protocol of a pragmatic 
randomized trial that is as similar as possible to the original trial and that the observational analysis will 
attempt to emulate—the target trial (26). The key components of the protocol of the target trial that 
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need to be specified are eligibility criteria, outcome, treatment strategies, start/end of follow-up, causal 
contrast and statistical analysis.  
 
In our case study, we defined the target trial protocol for HIV-CAUSAL to closely resemble the protocol 
of START. The central columns of Web Figure 1 summarize the harmonization of the protocols of START 
and of the target trial emulated by HIV-CAUSAL. In future references to these we refer to them as the 
‘actual’ and ‘emulated’ trials. The harmonization resulted in close, but not identical, protocols. For 
several components of the protocol, we had to find a reasonable compromise, as described below.  
 
Eligibility criteria  
The START trial required two CD4 counts>500 cells/mm3 at least 14 days apart within 60 days before 
randomization. In clinical practice, CD4 count is typically measured every 90-180 days and 
measurements 14-60 days apart are rare. As a compromise, the protocol of the emulated trial was 
modified to include individuals with at least two CD4 count>500 cells/mm3 within 90 days of each other. 
Baseline was defined as the randomization date in the actual trial and as the date of the second CD4 
count ≥500 cells/mm3 in the emulated trial. We excluded 9 START participants with no baseline HIV-RNA 
measurement within 60 days before randomization. 
 
START recruited participants from clinics in high, middle and low-income countries in 2009-2013 while 
HIV-CAUSAL included data from mostly high-income countries in 2000-2013. Restricting the actual trial 
to high-income countries would have resulted in too few events, so we did not impose geographic 
constraints in either study (and added Brazil to the emulated trial). Restricting to 2009-2013 was not 
possible in the emulated trial because of the substantial reduction in follow-up, so we restricted the 
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emulated trial to 2005-2013 as a compromise that resulted in comparable average follow-up between 
studies. 
 
Table 1 displays baseline characteristics of the 4676 eligible individuals in the actual trial and the 14,595 
in the emulated trial after harmonization. Participants in the two studies had similar distributions of 
baseline CD4 count, HIV-RNA, and age. The actual trial included a larger proportion of women and 
heterosexuals. The distribution of sex and risk group in the subset of 2769 START participants in high-
income countries was comparable to that in the emulated trial (Web Table 1).  
 
Treatment strategy 
Before harmonization the definition of the treatment strategies differed slightly between the actual and 
emulated trial protocols and the grace period during which an individual should initiate treatment was 
not specifically defined in the original START trial, while it was 6 months in the observational study. 
Because in practice it may take several weeks before treatment is started due to clinical tests and 
administrative procedures, we defined the grace period to be 1 month. We then defined the two 
treatment initiation strategies to be identical in the actual and emulated trial. In both studies, the 
strategies did not prescribe a particular pattern of treatment adherence after initiation. Predictors of 
protocol deviation in the START trial are described elsewhere (22). In the emulated trial, individuals who 
initiated ART within 1 month of baseline had similar characteristics to those who initiated ART later or 
never initiated ART (Web Table 2). 
 
Randomized assignment 
Randomized assignment to treatment strategies is the fundamental distinction between randomized 
and observational studies. In START, individuals were randomly allocated to one of the two treatment 
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strategies, which leads to the expectation of no unmeasured confounding at baseline, i.e., that the two 
groups are exchangeable at baseline (though not necessarily at later follow-up times) (27). In HIV-
CAUSAL, individuals are not randomly allocated so we assumed no unmeasured confounding at baseline 
conditional on measured prognostic factors that influence the timing of treatment such as CD4 count, 




In the actual and emulated trials follow-up started at baseline and ended at the earliest of outcome 
occurrence, loss to follow-up, and end of the study. Because the estimation of the per-protocol effect in 
both studies requires adjustment for post-baseline CD4 count and HIV-RNA, loss to follow-up was 
defined in the actual and emulated trial as 12 months without one of these measurements. After 
harmonization, the median follow-up was 35 months (interquartile range [IQR] 26, 47) in the actual trial 
and 32 months (IQR 16, 58) in the emulated trial. The proportion of individuals lost to follow-up in the 
first 5 years was 8% in the actual trial and 35% in the emulated trial. 
 
Outcome 
The original outcome was a composite endpoint encompassing serious AIDS, serious non-AIDS events 
and death in START and the earlier of death or any AIDS diagnosis in HIV-CAUSAL. Since information on 
non-AIDS events was not available in HIV-CAUSAL, the harmonized outcome definition was the same as 
in the original HIV-CAUSAL study (28). Because the START outcomes were restricted to adjudicated 
events only (9, 22) but AIDS events were not adjudicated in HIV-CAUSAL, we further defined the 
outcome to include any AIDS or death event regardless of adjudication. After harmonization, there were 
112 outcome events over 14,196 person-years in the actual trial, and 422 cases over 41,262 person-
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years in the emulated trial. The median [IQR] CD4 counts at which events occurred were 573 cells/mm3 
[444,711] in the actual trial and 560 cells/mm3 [426,700] in the emulated trial.  
 
Causal contrast 
The original studies used different causal contrasts: the original analysis of START estimated the 
intention-to-treat effect (9), whereas the HIV-CAUSAL study estimated the observational analog of the 
per-protocol effect: the effect that would have been observed under perfect adherence to the protocol 
(29). Because the magnitude of the intention-to-treat effect depends on the study-specific degree of 
adherence to the protocol, we chose to estimate the per-protocol effect in both the actual and 
emulated trials. 
 
Stage 2: Harmonization of data analysis 
The second stage of our systematic approach requires a reanalysis of both studies under the common 
target trial protocol. Specifically, for both studies, valid estimation of the per-protocol effect requires 
adjustment for baseline and post-baseline prognostic factors that predict treatment initiation and loss to 
follow-up. Because conventional methods cannot appropriately handle post-baseline prognostic factors 
that affect treatment status and are also affected by past treatment (i.e, treatment-confounder 
feedback), g-methods like inverse probability weighting or the g-formula should be used instead (27).  
 
In our case study, we assumed that the baseline variables in Table 1 and the post-baseline values of CD4 
count, HIV-RNA, timing of CD4 count and HIV-RNA measurement were sufficient to adjust for post-
baseline confounding. We used the parametric g-formula to estimate the per-protocol effect in both the 
actual and emulated trials. This method was used in the original analysis of HIV-CAUSAL (10) and in an 




The parametric g-formula is a generalization of standardization for time-varying treatments and 
confounders (30). It can be used to estimate the risk of the outcome that would have been observed if 
all individuals in the study had adhered to a particular treatment strategy and none had been lost to 
follow-up, under the assumptions of no residual confounding and selection bias, no measurement error, 
and no model misspecification. Briefly, the estimation procedure has two steps (10, 21, 31). First, we fit 
separate regression models for each of the post-baseline variables and for the outcome variable at each 
month as a function of previous treatment and covariate history and of baseline covariates. Second, for 
each treatment strategy, these models are used to simulate the outcome risk. 
 
For the first step, in both the actual and emulated trials, we fit separate logistic regression models for 
time-varying indicators of measurement of HIV-RNA, measurement of CD4 count, ART initiation, and the 
outcome and linear regression models for CD4 count and HIV-RNA on the natural logarithm scale. All 
models included as covariates restricted cubic splines with 5 knots (32) of the most recent value of CD4 
count, HIV-RNA, and time since last CD4 count and HIV-RNA measurements, and the following baseline 
variables: CD4 count, HIV-RNA, age, sex, mode of HIV acquisition, calendar year. In addition, models for 
the trial data were adjusted for income status of country (high versus middle and low income, according 
to the World Bank definition (33)) and models for the observational data were adjusted for geographical 
origin and cohort. All models included a product (“interaction”) term for number of months since 
treatment initiation. The placement of the knots of the splines and the thresholds for the baseline 
categories differed in the two studies. Nonparametric bootstrapping based on 500 samples was used to 




To explore the validity of our parametric assumptions, in both studies we compared the observed means 
of the outcome and time-varying covariates with those predicted by our models. The time-varying 
means predicted by our models under observed ART initiation were similar to the observed means in 
the original data (Web Figure 2-4). All analyses were conducted using the publicly available the 
GFORMULA_RCT and GFORMULA SAS macros (34, 35) 
 
Table 2 shows the estimated per-protocol effects of immediate vs. deferred treatment initiation in the 
harmonized studies. The estimated 5-year risk of AIDS or death under deferred treatment initiation was 
6.0% (95% confidence interval [CI] 4.4,8.1) in the actual trial and 5.1% (4.4,5.7) in the emulated trial. The 
corresponding estimated risk under immediate treatment initiation was higher in the emulated trial 
(3.0%; (2.3,3.7)) than in the actual trial (1.8%; (1.1,2.6)). As a consequence, the emulated trial estimated 
a smaller benefit of immediate initiation than the actual trial: a 5-year reduction in the absolute scale of 
2.1% (1.1,3.1) percentage points versus a reduction of 4.2% (2.5,6.3) percentage points. The estimated 
hazard ratio for deferred versus immediate treatment was 3.4 (2.1,6.2) in the actual trial and 1.63 
(1.28,2.32) in the emulated trial. The proportions of individuals who had initiated treatment under the 
deferred treatment initiation were comparable in the two studies (Web Figure 5). Because of the 
definition of the intervention, corresponding proportions under immediate treatment initiation was 
100% in both studies one month after baseline. These results were robust to the choice of placement of 
the spline knots. 
 
Stage 3: Sensitivity analyses to investigate remaining discrepancies 
The final stage of our systematic approach identifies components of the protocol that could not be fully 
harmonized and that, therefore, might explain the differences in effect estimates between the actual 
 
 14 
and emulated trials. Then a set of sensitivity analyses are conducted to explore the impact on the non-
harmonized components on the effect estimates. 
 
For our case study, Table 3 lists components of the protocol that we could not fully harmonize. We now 
describe the corresponding sensitivity analyses. 
 
Eligibility criteria 
The two studies might differ in the distribution of treatment effect modifiers. For example, the actual 
trial included a larger proportion of women, heterosexual individuals and individuals with baseline date 
on or after 2009 than the emulated trial. Because subgroup analyses are unfeasible given the large 
number of strata defined by these characteristics, we equalized (standardized) the distribution of the 
measured baseline factors between studies via the g-formula (the same can be achieved via inverse 
probability weighting (36, 37)). We simulated the risk in the subset of individuals in high-income 
countries in the actual trial if the joint distribution of measured covariates would have been that of the 
emulated trial. The procedure is illustrated in the flowchart in Web Figure 6. Any discrepancy between 
the original and standardized g-formula estimates can be attributed to differences in baseline 
characteristics.  
 
After standardization to the randomized trial’s baseline distribution, the estimated 5-year risk (95% CI) 
of AIDS or death in the actual trial was 3.6% (2.7, 4.8) under the immediate treatment strategy and 4.8% 
(4.3, 5.5) under the deferred treatment strategy. The similarity of these estimates with those reported in 
Table 2 suggests that the observed discrepancy cannot be fully explained by differences in the 




The implementation of the treatment strategies in the actual and emulated trials may have differed if 
the pattern of treatment discontinuation after treatment initiation varied between the studies. Because 
data on adherence after initiation was not available in HIV-CAUSAL, we compared the proportion of 
individuals with virological suppression (HIV-RNA<50 copies/mL), a proxy of adherence to ART, between 
both studies up to 5 years for each month after baseline. This proportion was similar in the two studies 
under deferred treatment initiation, but it was lower in the emulated trial under immediate initiation 
(Web Figure 7). Therefore, differential adherence after initiation might, in part, explain the discrepancy. 
 
The composition of ART regimens may have differed between the two studies. The proportions of 
individuals who initiated ART with a protease inhibitor regime and with a non-nucleoside reverse 
transcriptase inhibitor regime were 20% and 73% in the actual trial and 35% and 58% in the emulated 
trial. The proportion of individuals who initiated ART with an integrase inhibitor regime was similar in 
both studies (8% and 7%). Since non-nucleoside reverse transcriptase inhibitor and protease inhibitor 
regimes are, in general, similarly effective at controlling viral replication (38, 39), differences in initial 
ART regimes are unlikely to explain the discrepancy.  
 
Assignment procedure 
While the presence of unmeasured confounding cannot be empirically shown, there are indirect ways to 
explore this issue. For example, a difference in effect estimates early in the follow-up between the 
studies is suggestive of unmeasured confounding. In the actual trial, the 1-year risk was 0.6% (0,1.3) 
lower under immediate initiation (and the 2-year risk 1.7% (1.0,2.7) lower). In the emulated trial, no 
benefit was estimated in the 1-year risk (and only 0.4% (0,0.9) in 2-year risk). See Web Table 3 for more 
detailed results. This difference suggests that some individuals who started treatment early in the 
emulated trial might have had worse prognosis in a way that was not captured in the data. This 
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confounding might also partly explain why the effect estimates are attenuated in the emulated trial 
compared with the actual trial. 
 
Follow-up 
The proportion of individuals lost to follow-up at 24 months was 8% in the actual trial and 20% in the 
emulated trial. Because loss to follow-up in the emulated trial ranged between 14% and 41% across 
cohorts, we reran analyses restricted to the four cohorts with lowest follow-up rate (Swiss HIV Cohort 
Study, CoRIS, PISCIS and French Hospital Database): the risk of AIDS or death was 3.0% (2.1,3.9) for 
immediate initiation and 4.6% (3.8,5.5) for deferred initiation, which are similar to those estimated in 
Table 2 (3.0% and 5.0%). Also, because the higher loss to follow-up in the emulated trial may be the 
result of including some individuals not fully engaged in HIV care, we conducted analyses excluding 
individuals who were lost early. The risk of AIDS or death were 3.1% (2.3,3.8) for immediate initiation 
and 5.2% (4.5,5.7) for deferred initiation after excluding individuals who were lost by 12 months, and  
3.3% (2.5,4.1) and 5.5% (4.8,6.0) after excluding individuals who were lost by 12 months. In summary, 
differences in loss to follow-up seem unlikely to explain the discrepancy.  
 
Outcome 
The emulated trial included only centers from high-income countries where tuberculosis is rare, while 
the actual trial included data from middle- and low-income countries where tuberculosis is more 
common. In the harmonized analyses 28% of outcome events in the actual trial were tuberculosis, but 
only 5% in the emulated trial. Unlike other opportunistic infections, tuberculosis can occur early in the 
course of the HIV infection and at high CD4 cell count (40, 41). An obvious sensitivity analysis would 
have been to redefine the outcome excluding tuberculosis, but the small number of outcome events in 
the immediate initiation group of START prevented us from doing this. A differential effect of the 
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We proposed a 3-step approach for the comparison of effect estimates from existing randomized trials 
and observational studies based on routinely collected data: 1) harmonization of the causal question, 2) 
harmonization of data analysis, and 3) sensitivity analyses to examine the impact of any remaining 
discrepancies that could not be accounted for in the harmonization process. We applied this general 
approach to comparison of the effect of immediate vs. deferred antiretroviral treatment initiation in 
HIV-positive individuals with CD4>500 cells/mm3. After harmonization, the 5-year risk difference of AIDS 
or death for deferred versus immediate treatment was 4.2% in START and 2.1% in HIV-CAUSAL. These 
results reinforce the current recommendations of initiating treatment as early as possible in HIV-positive 
individuals. Our 3-step approach can be applied to any randomized-observational comparison. 
 
The harmonized risk under deferred treatment was similar in the randomized trial and in the 
observational study, but the harmonized risk under immediate initiation was higher in the observational 
study. Four differences which could not be fully harmonized might explain this difference: (i) residual 
confounding in the observational study (supported by the poor prognosis of individuals who started 
treatment soon after baseline even after adjusting for the measured prognostic factors), (ii) lower 
adherence to treatment after immediate initiation in the observational study (supported by lower 
proportion of virological suppression, a proxy for adherence), (iii) higher proportion of tuberculosis 
events in the randomized trial (the benefit of early initiation might be more pronounced for 
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tuberculosis), and (v) overestimation of the beneficial effect of immediate treatment initiation in the 
randomized trial due to early stopping after an interim analysis indicating a benefit (42, 43).   
 
Whatever the remaining differences, the harmonized estimates from the randomized trial and 
observational study were in the same neighborhood. In contrast, a previous observational analysis (18), 
which did not appropriately emulate a target trial (44), yielded an implausible hazard ratio estimate of 
0.51 for immediate vs delayed initiation when the outcome was death only (as opposed to AIDS or death 
in our analysis), the median follow-up was less than 24 months (as opposed to 35 months in our 
analysis), and a 6-month grace period (as opposed to 1 month in our analysis).   
 
In contrast with previous comparisons of observational studies based on meta-analysis (4-8) and within 
study comparison (45), our approach requires the reanalysis of two two existing studies and will often 
result in an imperfect harmonization. For example, in our case study several factors may have also 
contributed to the observed-randomized difference, as we could not fully harmonize some eligibility 
criteria, the definition of outcome, and the clinical setting. Future work can extend our general 
framework to incorporate quantitative assessments of the impact of imperfect harmonization on the 
randomized-observational discrepancies (46, 47). 
 
A reanalysis is often required because the primary inferential target of most randomized trials is the 
intention-to-treat effect (e.g., the effect of treatment assignment, regardless of adherence to the 
treatment), which may not be directly transportable to populations outside of the study with different 
adherence patterns. Therefore, we used a per-protocol approach to compare the randomized and 
observational estimates, which required a re-analysis of the randomized trial data. In addition, both 
observational and randomized estimates need to be adjusted for potential selection bias due to loss to 
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follow-up, which may also require a re-analysis of the randomized trial data. The validity of per-protocol 
effect estimates from both the randomized trial and the observational study relies on untestable 
assumptions of no unmeasured confounding (3). 
 
In summary, comparisons of randomized trials and observational studies need to explicitly consider 
differences in components of the study design and statistical analysis. Our approach provides a 
structured framework to compare effect estimates from randomized trials and observational studies, 
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Table 1. Participants’ characteristics at baseline after harmonization in START (actual trial) and the HIV-CAUSAL Collaboration (emulated trial) 
 
Characteristics at baseline Actual trial (4676) Emulated trial (14,595) 
 Median (interquartile range) N % Median [interquartile range] 
CD4 cell count, median [IQR] cells/mm3   a 651 (584,765)   559 (585,779) 
Enrollment year, median [IQR]   2012 (2011,2013)   2009 (2007,2011) 
Age, median [IQR]   36 (29,44)   36 (29,43) 
HIV-RNA, median copies/mL[IQR]   12759 (3019,43391)   17469 (4300,57539) 
Females  1253 27%  
HIV acquisition risk group     
   MSM  1787 38%  
   MSW or WSM  25814 55%  
   IDU  64 1%  
    Other/Unknown   244 5%   




MSM: men who have sex with men; MSW: men who have sex with women; WSM: women who have sex with men; IDU: injecting drug use 
a. Average of two baseline values 












Table 2. Per-protocol effect estimates of the 5-year risk, risk difference and hazard ratios of AIDS or death in START (actual trial) and in HIV-
CAUSAL Collaboration (emulated trial) after harmonization. 
 
Treatment strategy Risk (%) 95% CI 






Actual trial a         
Immediate treatment 1.8 1.1,2.6 Ref Ref Ref Ref 
Deferred treatment 6 4.4,8.1 4.2 2.5,6.3 3.4 2.1,6.2 
Emulated trial b        
Immediate treatment 3 2.3,3.7 Ref Ref Ref Ref 
Deferred treatment 5.1 4.4,5.7 2.1 1.1,3.1 1.6 1.3,2.3 
a. N=4,676; 112 events 




Table 3. Possible explanations for differences in estimates from the randomized START and the HIV-





Examples Proposed sensitivity 
analyses 
Eligibility criteria Differences in the 
patient mix  
START included more 
women and heterosexual 
individuals 
Standardization 
Treatment strategy Differences in 
treatment uptake 
Individuals in START might 
be more adherent than 
individuals in HIV-CAUSAL 
Compare treatment 
adherence (or a proxy) in the 
observed and emulated trials 
at 1,2,3,4, and 5 years    
Individuals in the two 
studies might have received 
ART combinations with 
different efficacy 
Compare distribution of 





Individuals who started ART 
with high CD4 count n HIV-
CAUSAL might have worse 
prognosis 
Estimate and compare 
treatment effects in the two 
studies at 1,2,3, 4 and 5 years 
Follow-up Differential loss to 
follow-up 
In HIV-CAUSAL individuals 
who are lost to follow-up 
tend to have high CD4 
count 
Re-analysis excluding 
individuals who were lost to 
follow-up in the first 12 or 24 
months since baseline  
Outcome Differences in baseline 
risk for the outcome 
Individuals in START might 
have a larger risk of 
tuberculosis than in HIV-
CAUSAL 
Re-analysis excluding cases of 
tuberculosis as events (if 
possible)  
ART: antiretroviral therapy;
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